Telomir Pharmaceuticals, Inc | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Headlines Articles Press releases Telomir Pharmaceuticals, Inc

Home
Companies
Telomir Pharmaceuticals, Inc

BRIEF

published on 10/14/2025 at 14:05, 1 month 21 days ago

Telomir Pharmaceuticals Reports Progress in Pancreatic Cancer Research

Pancreatic Cancer Biotechnology Research Telomir-1 Epigenetic Regulation Cancer Cell Survival
PRESS RELEASE

published on 10/14/2025 at 14:00, 1 month 21 days ago

Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer
Telomir Pharmaceuticals announces new laboratory findings showing Telomir-1's impact on aggressive pancreatic cancer cells, revealing potential therapeutic pathways for treatment

Pancreatic Cancer Telomir-1 Telomir Pharmaceuticals Laboratory Findings Therapeutic Pathways
BRIEF

published on 10/09/2025 at 13:35, 1 month 26 days ago

Telomir Pharmaceuticals Unveils Breakthrough Against Aggressive Breast Cancer

Telomir-1 Telomir Pharmaceuticals Epigenetic Therapy Triple-negative Breast Cancer Iron Regulation
PRESS RELEASE

published on 10/09/2025 at 13:30, 1 month 26 days ago

Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells
Telomir Pharmaceuticals announces new findings showing Telomir-1's impact on aggressive breast cancer cells, targeting iron-dependent regulation and cellular energy pathways

Telomir-1 Telomir Pharmaceuticals Breast Cancer Cells Iron-dependent Regulation Cellular Energy Pathways
BRIEF

published on 10/07/2025 at 13:35, 1 month 28 days ago

Telomir Pharmaceuticals Unveils Promising Preclinical Results in Prostate Cancer Therapy

Prostate Cancer Telomir-1 Telomir Pharmaceuticals Epigenetic Therapy Tumor Suppressors
PRESS RELEASE

published on 10/07/2025 at 13:30, 1 month 28 days ago

Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance
Telomir Pharmaceuticals unveils new preclinical findings showing Telomir-1 reactivates tumor suppressor genes MASPIN and RASSF1A in aggressive prostate cancer models, offering potential for improved chemotherapy response and metastasis control

Prostate Cancer Telomir-1 Telomir Pharmaceuticals Preclinical Findings Tumor Suppressor Genes
BRIEF

published on 09/18/2025 at 14:05, 2 months 16 days ago

Telomir-1 Shows Expanded Targeting of Histone Demethylases

Telomir-1 Telomir Pharmaceuticals Epigenetic Therapy Histone Demethylases Cancer And Aging
PRESS RELEASE

published on 09/18/2025 at 14:00, 2 months 16 days ago

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies
Telomir Pharmaceuticals announces Telomir-1's new in vitro results inhibiting KDM5 family, expanding epigenetic therapy possibilities in cancer treatment and aging slowdown

Telomir-1 Telomir Pharmaceuticals Epigenetic Therapy KDM5 Family Inhibition Cancer Aging Treatment
BRIEF

published on 09/09/2025 at 14:05, 2 months 25 days ago

Telomir Pharmaceuticals Unveils Promising Preclinical Cancer Data

Cancer Research Telomir-1 Telomir Pharmaceuticals DNA Methylation CDKN2A
PRESS RELEASE

published on 09/09/2025 at 14:00, 2 months 25 days ago

Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy
Telomir Pharmaceuticals announces new preclinical findings showing Telomir-1's ability to reverse CDKN2A gene silencing by DNA methylation, potentially restoring cancer cell cycle control and immune surveillance

Cancer Therapy Telomir Pharmaceuticals Preclinical Findings DNA Methylation CDKN2A Gene

Accesswire

Published on 12/05/2025 at 02:35, 3 hours 52 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 3 hours 57 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 27 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 22 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 27 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 2 hours 57 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 36 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 2 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 12 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 17 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 12 hours 27 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 42 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 43 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 26 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE